Summer Street says investors too negative on Rigel Pharmaceuticals Summer Street says it is not concerned that AstraZeneca (AZN) returned fostamatinib to Rigel Pharmaceuticals (RIGL). It believes investors are too negative on Rigel and that the company filing a new drug application for fostamatinib for rheumatoid arthritis should be a positive catalyst for shares.
News For RIGL;AZN From The Last 14 Days
Check below for free stories on RIGL;AZN the last two weeks.
Leerink's biotech/pharma analysts hold an analyst/industry conference call Biotech Analyst Kozul and Major Pharmaceuticals Analyst Fernandez provide a review of Emerging 3rd Generation Tyrosine Kinas Inhibitors (TKI) Data for Non-Small Cell Lung Cancer (NSCLC) on an Analyst/Industry conference call. Relevant companies AstraZeneca (AZN) and Clovis Oncology (CLVS) may be discussed on the Analyst/Industry conference call to be held on December 12 at 1 pm.